Filing Flows › Regenxbio (RGNX) › Q2 2026 › vs Q1 2026
Regenxbio (RGNX) Q2 2026 vs Q1 2026 (quarter over quarter)
Regenxbio's revenue rose $102M (17×) from $6.4M in Q1 2026 to $108M in Q2 2026.
Regenxbio, Q2 2026: revenue $108M (+406% year over year), operating margin 27.1%, net earnings $22.7M, operating cash flow −$62.2M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $108M | $6.4M | $102M | 17× |
| Operating profit | $29.3M | −$83.4M | $113M | — |
| Costs & expenses | $78.8M | $89.8M | −$11.0M | -12% |
| Pre-tax earnings | $22.7M | −$90.1M | $113M | — |
| Other expense, net | $6.6M | $6.7M | −$135K | -2% |
| Research & development | $56.1M | $57.3M | −$1.3M | -2% |
| General & admin | $21.6M | $21.3M | $310K | +1% |
| Other operating costs | $1.1M | $11.1M | −$10.1M | -91% |
| Net earnings | $22.7M | −$90.1M | $113M | — |
| Operating cash sources | $97.8M | −$1.4M | $99.1M | — |
| Depreciation & amortization | $3.8M | $3.9M | −$100K | -3% |
| Share-based compensation | $9.1M | $8.6M | $436K | +5% |
| Cash used in operations | $62.2M | $76.2M | −$13.9M | -18% |
| Working capital & other | $97.8M | −$1.4M | $99.1M | — |
Questions
How much did Regenxbio's revenue grow quarter over quarter in Q2 2026?
Regenxbio's revenue rose $102M (17×) from $6.4M in Q1 2026 to $108M in Q2 2026.